1. PMDA. https://www.pmda.go.jp/english/about-pmda/outline/0002.html [accessed 22 March 2021]
2. https://elaws.e-gov.go.jp/document?lawid=335AC0000000145 (Japanese) [accessed 22 March 2021].
3. Ministry of Health, Labour and Welfare (MHLW). https://www.mhlw.go.jp/web/t_doc?dataId=81006000&dataType=0&pageNo=1 (Japanese) [accessed 22 March 2021].
4. MHLW. https://www.mhlw.go.jp/web/t_doc?dataId=00ta6846&dataType=1&pageNo=1 (Japanese) [accessed 22 March 2021].
5. MHLW. https://www.mhlw.go.jp/shingi/2005/01/dl/s0124-9h1.pdf (Japanese) [accessed 22 March 2021].
6. MHLW. https://www.hospital.or.jp/pdf/14_20040709_01.pdf (Japanese) [accessed 22 March 2021].
7. MHLW. https://www.hospital.or.jp/pdf/18_20100830_01.pdf (Japanese) [accessed 22 March 2021].
8. MHLW. https://www.nibiohn.go.jp/nibio/part/promote/files/48f09eb927520a338f402e9150d960be0969b81e.pdf (Japanese) [accessed 22 March 2021].
9. PMDA. https://www.pmda.go.jp/english/review-services/reviews/advanced-efforts/0001.html [accessed 22 March 2021].
10. PMDA. https://www.pmda.go.jp/files/000227089.pdf [accessed 22 March 2021].
11. PMDA. https://www.pmda.go.jp/review-services/drug-reviews/0002.html (Japanese) [accessed 22 March 2021].
12. MHLW. https://www.mhlw.go.jp/content/11120000/000666236.pdf (Japanese) [accessed 22 March 2021].
13. PMDA. https://www.pmda.go.jp/english/safety/info-services/drugs/rmp/0001.html [accessed 22 March 2021].
14. MHLW. https://www.pmda.go.jp/files/000206740.pdf (Japanese) [accessed 22 March 2021].
15. H Maeda, T Kurokawa. Acceptance of Surrogate End Points in Clinical Trials Supporting Approval of Drugs for Cancer Treatment by the Japanese Regulatory Agency. Ann Oncol. 2015 Jan;26(1):211-216.
16. Amy E McKee, Ann T Farrell, Richard Pazdur, Janet Woodcock. The Role of the U.S. Food and Drug Administration Review Process: Clinical Trial Endpoints in Oncology. Oncologist. 2010;15 Suppl 1:13-18.
17. FDA. https://www.fda.gov/files/drugs/published/Expedited-Programs-for-Serious-Conditions-Drugs-and-Biologics.pdf [accessed 22 March 2021].
18. Huseyin Naci, Katelyn R Smalley, Aaron S Kesselheim. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration. JAMA. 2017 Aug 15;318(7):626-636.
19. FDA. https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=718f6fcbc20f2755bd1f5a980eb5eecd&mc=true&n=sp21.5.316.c&r=SUBPART&ty=HTML#se21.5.316_120 [accessed 22 March 2021].
20. FDA. https://www.fda.gov/drugs/real-time-review-drug-applications-now-reality-september-20-2018-issue [accessed 22 March 2021].
21. Obama B. Video and transcript: President Obama: Speech on the Precision Medicine Initiative. January 30, 2015. Available at: http://www.shallownation.com/2015/01/30/president-obama-speech-precision-medicine-initiative-jan-30-2015-white-house/#sthash.Elu9WMPm.dpuf [accessed 22 March 2021].
22. Marjorie Zettler, Ethan Basch, Chadi Nabhan. Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs Approved Between 2011 and 2017. JAMA Oncol. 2019 Jul 3;5(9):1358-1359.
23. EMA. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/accelerated-assessment [accessed 22 March 2021].
24. EMA. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation [accessed 22 March 2021].
25. EMA. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/pre-authorisation-guidance [accessed 22 March 2021].
26. EMA. https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation/legal-framework-orphan-designation [accessed 22 March 2021].
27. EMA. https://www.ema.europa.eu/en/news/launch-prime-paving-way-promising-medicines-patients [accessed 22 March 2021].
28. Hideki Origasa, Naoko Kumagai, Shigeki Sumi. Using and Validating Surrogate Endpoints Toward Accelerated Approvals. Jpn Pharmacol Ther 2009; 37: 633-639.
29. FDA. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics [accessed 22 March 2021].
30. Courtney Davis, Huseyin Naci, Evrim Gurpinar, Elita Poplavska, Ashlyn Pinto, Ajay Aggarwal. Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals 2009-13. BMJ. 2017 Oct 4;359:j4530.
31. MHLW. https://public-comment.e-gov.go.jp/servlet/PcmFileDownload?seqNo=0000216748 (Japanese) [accessed 7 April 2021].
32. Takehiro Hirai, Asuka Nemoto, Yoshinori Ito, Masaaki Matsuura. Meta-analyses on Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Triple-Negative Breast Cancer. Breast Cancer Res Treat. 2020 May;181(1):189-198.
33. National Cancer Center Japan. https://www.ncc.go.jp/jp/cras/biostatistics/Symposium/symposium.html (Japanese) [accessed 7 April 2021].
34. Japan Pharmaceutical Manufacturers Association. http://www.jpma.or.jp/opir/news/061/pdf/no61_p59.pdf (Japanese) [accessed 7 April 2021].